The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Targeting TGF-β Signaling for Therapeutic Gain2017 · 240 citations
2. 2Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group2017 · 2,020 citations
3. 3Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer2020 · 140 citations
4. 4T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer2021 · 18 citations
5. 5TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer2018 · 124 citations